Piramal Pharma Limited (NSE:PPLPHARMA)

Market Cap	197.57B -32.0%
Revenue (ttm)	88.71B -0.9%
Net Income	-1.64B
EPS	-1.24
Shares Out	1.33B
PE Ratio	n/a
Forward PE	102.29
Dividend	0.14 (0.09%)
Ex-Dividend Date	Jul 16, 2025

Volume	2,298,503
Average Volume	3,150,878
Open	149.00
Previous Close	148.79
Day's Range	148.90 - 151.99
52-Week Range	132.30 - 228.45
Beta	0.19
RSI	57.40
Earnings Date	Apr 28, 2026

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, inje...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 5,476
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PPLPHARMA

Financial Performance

In fiscal year 2025, Piramal Pharma's revenue was 91.51 billion, an increase of 11.99% compared to the previous year's 81.71 billion. Earnings were 911.30 million, an increase of 411.39%.